25 March 2019
Visiongain has launched a new pharma report Top 50 Bioreactor Manufacturers 2019: Danaher Corporation, Eppendorf AG, GE Healthcare, Merck KGaA, Thermo Fisher, Sartorius AG, Bioengineering AG and Others.
The biopharmaceutical contract manufacturing market has significantly expanded over the past years. The rising interest of pharmaceutical organizations to enter the biopharmaceutical market will result in consolidation in the form of strategic alliances between contract manufacturing organizations (CMO’s) and large pharmaceutical/biotechnology organizations. This will result in increased investments and access to cutting-edge manufacturing technologies for CMOs.
Factors driving the bioreactors market growth include massive use of hybrid technologies, rise in the rate of adoption of single-use technologies, increasing popularity of single-use bioreactor among biopharmaceutical organizations, and a significant growth in the biologics market. However, regulatory challenges pertaining to single-use bioreactors and issues concerning leachable and extractable linked to single-use bags are some of the factors hampering the growth of bioreactors market.
The lead analyst of the report commented "The bioreactors market is expected to grow over the forecast period owing to the increase in adoption of single use technologies and the growing popularity among pharmaceutical companies regarding the potential benefits of single-use bioreactors. In addition, the use of hybrid technologies in bioprocessing also fuels the market growth. However, there are few restraints which might impede the growth of the market such as regulatory concerns and problems associated to single-use bags which are extractable and leachable."
Leading companies featured in the report include Applikon Biotechnology Inc. (U.S.), BBI-Biotech GmbH (Germany), Bioengineering AG (Switzerland), Danaher Corporation (U.S), Eppendorf AG (Germany), GE Healthcare (A subsidiary of General Electric Company) (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Solaris Biotech (Italy), Thermo Fisher Scientific, Inc. (U.S.) and others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market for ophthalmic drugs is a growing one.
17 June 2019
Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.
14 June 2019
The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.
06 June 2019
Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.